Jafron Biomedical Co.,Ltd. (SHE:300529)

Jafron Biomedical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	1,725	2,810	2,559	2,319	1,575
Trading Asset Securities	593.07	-	-	150.01	-
Cash & Short-Term Investments	2,318	2,810	2,559	2,469	1,575
Cash Growth	-17.52%	9.83%	3.62%	56.79%	23.85%
Accounts Receivable	55.61	81.21	239.64	308.06	215.8
Other Receivables	3.66	6.51	6.85	6.32	9.78
Receivables	59.27	87.72	246.49	314.37	225.58
Inventory	337.79	385	349.13	196.55	120.67
Prepaid Expenses	-	0.32	14.55	-	-
Other Current Assets	68.81	28.5	124.32	75.27	65.31
Total Current Assets	2,784	3,312	3,293	3,056	1,987
Property, Plant & Equipment	1,894	1,771	1,672	1,272	905.51
Long-Term Investments	446.13	116.13	69.45	111.2	98.99
Goodwill	7.01	12.21	37.81	44.07	44.07
Other Intangible Assets	97.75	100.37	100.43	101.31	89.89
Long-Term Deferred Tax Assets	34.97	30.35	36.49	26.54	12.97
Long-Term Deferred Charges	87.19	94.87	59	35.95	20.42
Other Long-Term Assets	32.35	107.03	148.22	162.91	58.22
Total Assets	5,383	5,543	5,417	4,810	3,217
Accounts Payable	119.19	135.62	128.52	60.76	50.22
Accrued Expenses	125.07	158.21	157.48	192.98	139.79
Short-Term Debt	77.51	261.83	317.09	-	-
Current Portion of Long-Term Debt	192.2	16.79	-	-	-
Current Portion of Leases	1.83	3.83	4.73	3.17	-
Current Income Taxes Payable	56.63	30.52	2.55	23.19	52.14
Current Unearned Revenue	16.86	37.57	42.3	20.65	26.95
Other Current Liabilities	177.51	185.03	64.52	85.51	61.73
Total Current Liabilities	766.79	829.42	717.18	386.26	330.82
Long-Term Debt	1,110	1,381	936.78	897.37	-
Long-Term Leases	4.74	11.35	17.34	17.01	-
Long-Term Unearned Revenue	144.95	151.78	151.66	125.08	51.7
Long-Term Deferred Tax Liabilities	16.11	16.78	3.12	0.73	0.54
Other Long-Term Liabilities	6	-	-	-	-
Total Liabilities	2,049	2,390	1,826	1,426	383.06
Common Stock	798.61	807.56	807.71	805.5	799.11
Additional Paid-In Capital	231.26	694.14	678.04	618	347.9
Retained Earnings	2,918	2,408	2,507	2,336	1,670
Treasury Stock	-733.82	-880.63	-509.69	-523.8	-13.52
Comprehensive Income & Other	119.69	118.63	91.7	123.14	3.08
Total Common Equity	3,334	3,147	3,574	3,359	2,807
Minority Interest	0.76	5.4	16.17	24.79	26.82
Shareholders' Equity	3,335	3,153	3,590	3,384	2,834
Total Liabilities & Equity	5,383	5,543	5,417	4,810	3,217
Total Debt	1,386	1,675	1,276	917.55	-
Net Cash (Debt)	931.31	1,135	1,283	1,552	1,575
Net Cash Growth	-17.97%	-11.49%	-17.34%	-1.47%	23.85%
Net Cash Per Share	1.19	1.43	1.62	1.93	1.94
Filing Date Shares Outstanding	774.36	774.47	798.87	815.46	798.53
Total Common Shares Outstanding	774.36	774.47	798.86	815.46	799.11
Working Capital	2,017	2,482	2,576	2,669	1,656
Book Value Per Share	4.31	4.06	4.47	4.12	3.51
Tangible Book Value	3,229	3,035	3,436	3,213	2,673
Tangible Book Value Per Share	4.17	3.92	4.30	3.94	3.34
Buildings	1,296	1,260	890.61	812.74	555.36
Machinery	764.58	678.23	514.6	304.98	212.71
Construction In Progress	244.45	122.43	473.99	301.15	262.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.